A Pilot Trial Evaluating Maintenance Therapy With Lamivudine(Epivir) and Dolutegravir(Tivicay) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple HAART - ANRS 167 Lamidol
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms ANRS167 LAMIDOL
- 21 Jul 2021 Results assessing the proportion of APOBEC3F/3G defective viruses in PBMC from ARV-treated patients with prolonged virological suppression, presented at the 11th International AIDS Society Conference on HIV Science
- 11 Mar 2020 Results (n=96) assessing factors between drug concentration and body weights in HIV-1-infections patients were presented at the 27th Conference on Retroviruses and Opportunistic Infections
- 24 Feb 2020 Results of pharmacovirological analysis describing plasma residual HIV viraemia, cellular HIV reservoir size, blood plasma drug concentrations and their male genital tract penetration during the maintenance dual therapy dolutegravir + lamivudine published in the Journal of Antimicrobial Chemotherapy